-
RedHill gets DSMB recommendation to continue Phase II/III Covid-19 study
pharmaceutical-technology
December 23, 2020
RedHill Biopharma has received a second unanimous DSMB recommendation to continue the global Phase II/III study of opaganib (Yeliva, ABC294640) in patients hospitalised with severe Covid-19 pneumonia.
-
RedHill to Continue Phase 2/3 COVID-19 Study with Opaganib
americanpharmaceuticalreview
December 04, 2020
RedHill Biopharma announced that the global Phase 2/3 study with opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia has received a unanimous recommendation to continue, following a pre-scheduled safety review by an ...
-
Stem cell therapy trial for COVID-19 patients with ARDS advised to continue
europeanpharmaceuticalreview
November 13, 2020
The trial’s independent Data Safety Monitoring Board (DSMB) recommended that the Phase III study evaluating remestemcel-L continue based on the second interim analysis.
-
SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis
prnasia
November 09, 2020
SynAct Pharma AB, a clinical stage biopharmaceutical company developing novel therapies of inflammatory diseases, today announced that an independent Data Safety Monitoring Board (DSMB) has reviewed unblinded and validated data from part 1 of the ...
-
Humanigen announces positive interim data of Lenzilumab in hospitalised COVID-19 patients
expresspharma
November 09, 2020
The company intends to file for EUA in the first quarter of 2021 either following interim data at 75 per cent or at study completion.
-
BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial
biospace
March 08, 2018
BioTime, Inc. announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the fourth cohort for the ongoing OpRegen® clinical trial